News
Ireland's Genable Technologies Completes an €5M Series B Financing
11th November 2011
Genable Technologies, (Dublin, Ireland) successfully completed a new financing round for ?5m led by new investors Fountain Healthcare Partners alongside existing investors Delta Partners. This funding will support the on-going development of Genable's suppression/replacement gene therapy technology and specifically progress Genable's lead product GT038 for Retinitis Pigmentosa (RP) forward into clinical evaluation in man.
GT083 Granted orphan drug designation by the European Medicines Agency
31st January 2011
On 17th December 2010 orphan designation (EU/0/00/000) was granted by the European Medicines Agency (EMA) to Genable Technologies Ltd, Ireland, for GT038, an adeno-associated viral (AAV) based therapy containing DNA encoding an RNAi targeting rhodopsin and a replacement rhodopsin gene for the treatment of rhodopsin-linked Retinitis Pigmentosa.
Genable Technologies to present at XVIIITH Annual congress of the European Society of Gene & Cell therapy
21st October 2010
Genable Technologies will present data on their novel approach for the treatment of RHODOPSIN-LINKED AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA – a leading cause of blindness - at the XVIIITH ANNUAL CONGRESS OF THE EUROPEAN SOCIETY OF GENE & CELL THERAPY in Milan this weekend.
Genable adds industry experience to its board
6th October 2005
Genable Technologies Ltd, a bio-pharmaceutical company developing new gene medicines to treat inherited blindness, has appointed two directors to its board: Dr John Monahan, founder and former Chief Executive Officer of Avigen, Inc. (NASDAQ: AVGN); and, Dr Alan Boyd, former Research and Development Director of Ark Therapeutics Ltd (LSE: Ark).
Genable raises first round venture capital investment
1st September 2004
Genable Technologies, an early stage Irish biotechnology company, has raised €1.1 million in an investment round led by Delta Partners. Genable is developing gene-based therapies for the treatment of incurable inherited diseases. Its focus and world-leading position is in "dominant negative" diseases such as retinitis pigmentosa, which causes blindness. The company's technology platform provides for the suppression and replacement of genes. Developed from over 10 years of research, it is now entering into pre-clinical studies.
